Hereditary angioedema (HAE) is a severe, unpredictable, rare disease which can result in life-threatening swelling attacks. Our aim was to position Takhzyro®▼ as the number one choice for long-term prevention of HAE attacks and more broadly, move further towards zero attacks as SoC whilst optimising patients’ access to Takhzyro, with the launch in January 2020.
Six months after launch, 52 HAE patients are accessing treatment and sales were 60% above expectations. We partnered with HAE UK, the leading patient organisation and the launch gained coverage in all top trade outlets. Takhzyro’s cost-effectiveness was presented to over 50% of priority accounts.